Gonadotropin-Releasing Hormone (GnRH) Agonist: A class of drugs that mimic the action of GnRH, a hormone responsible for stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a paradoxical suppression of gonadal hormone production.
Androgen Deprivation Therapy (ADT): A treatment approach that aims to reduce the levels of male hormones, particularly testosterone, to prevent the growth and progression of hormone-sensitive cancers, such as prostate cancer.
Prostate-Specific Antigen (PSA): A protein produced by the prostate gland, which can be used as a biomarker to monitor the progression and response to treatment in prostate cancer.